Genmab A/S - American Depositary Shares (NQ:GMAB)

27.91 -0.81 (-2.82%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 20, 2026 Add to My Watchlist

Price and Volume

Volume	1,244,858
Open	28.65
Bid (Size)	27.80 (300)
Ask (Size)	30.00 (100)
Prev. Close	28.72
Today's Range	27.86 - 28.80
52wk Range	21.00 - 35.43
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

July 06, 2026

From Genmab A/S

Via Business Wire

Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival

June 29, 2026

From Genmab A/S

Via Business Wire

Performance

YTD	-12.3%	-12.3%
1 Month	+9.0%	+9.0%
3 Month	N/A	N/A
6 Month	-10.9%	-10.9%
1 Year	+28.7%	+28.7%

More News

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

June 13, 2026

From Genmab A/S

Via Business Wire

Genmab A/S -SP ADR (NASDAQ:GMAB) Presents a Compelling Value Investment Case ↗

March 05, 2026

Via Chartmill

GENMAB A/S -SP ADR (NASDAQ:GMAB) Emerges as a Peter Lynch-Style GARP Investment ↗

February 20, 2026

Via Chartmill

Genmab Presents EPCORE® FL-1 Subgroup Data Demonstrating Consistent Efficacy and Safety Results for Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Across Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Patients

June 11, 2026

From Genmab

Via Business Wire

Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress

May 21, 2026

From Genmab A/S

Via Business Wire

Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer

April 13, 2026

From Genmab A/S

Via Business Wire

Genmab A/S (NASDAQ:GMAB): A GARP Case Study in Affordable Biotech Growth ↗

February 06, 2026

Via Chartmill

GENMAB A/S (NASDAQ:GMAB) Stands Out as a Peter Lynch-Style GARP Investment ↗

January 29, 2026

Via Chartmill

Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential? ↗

March 22, 2026

Via The Motley Fool

AbbVie Shares Retreat to Multi-Month Lows Amid Competitive Headwinds and Technical Breakdown

March 18, 2026

Via MarketMinute

GENMAB A/S -SP ADR (NASDAQ:GMAB) Combines Strong Growth with Bullish Technical Formation ↗

January 26, 2026

Via Chartmill

GENMAB A/S (NASDAQ:GMAB) Presents a Compelling Blend of Strong Fundamentals and Bullish Technicals ↗

January 24, 2026

Via Chartmill

GENMAB A/S -SP ADR (NASDAQ:GMAB) Passes Peter Lynch's GARP Investment Screen ↗

December 31, 2025

Via Chartmill

My Top 4 Stocks to Buy in Early 2026 ↗

January 22, 2026

Via The Motley Fool

Genmab Reports Mixed Results From Late-Stage Trial Of Lymphoma Drug ↗

January 16, 2026

Via Stocktwits

Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

January 16, 2026

From Genmab A/S

Via Business Wire

Why Are Investors Paying Attention To Genmab Stock? ↗

January 07, 2026

Via Benzinga

Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence

January 07, 2026

From Genmab A/S

Via Business Wire

Genmab Stock Slips After Discontinuing Further Development Of Cancer Drug Developed With BioNTech ↗

December 29, 2025

Via Stocktwits

Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal

December 29, 2025

Via MarketMinute

Genmab Portfolio Prioritization Update

December 29, 2025

From Genmab A/S

Via Business Wire

Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period

December 12, 2025

From Genmab A/S

Via Business Wire

Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma

December 07, 2025

From Genmab A/S

Via Business Wire

Frequently Asked Questions

Is Genmab A/S - American Depositary Shares publicly traded?

Yes, Genmab A/S - American Depositary Shares is publicly traded.

What exchange does Genmab A/S - American Depositary Shares trade on?

Genmab A/S - American Depositary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for Genmab A/S - American Depositary Shares?

The ticker symbol for Genmab A/S - American Depositary Shares is GMAB on the Nasdaq Stock Market

What is the current price of Genmab A/S - American Depositary Shares?

The current price of Genmab A/S - American Depositary Shares is 27.91

When was Genmab A/S - American Depositary Shares last traded?

The last trade of Genmab A/S - American Depositary Shares was at 07/20/26 04:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.